Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 17Lymphoma 16Multiple Myeloma 13Neoplasm Metastasis 10Leukemia, Myeloid, Acute 10Melanoma 9Lung Neoplasms 9Prostatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 6Lymphoma, Non-Hodgkin 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Neuroblastoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Follicular 4Burkitt Lymphoma 4Wilms Tumor 3Small Cell Lung Carcinoma 3Sarcoma, Kaposi 3Sarcoma 3Rhabdoid Tumor 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precancerous Conditions 3Ovarian Neoplasms 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Medulloblastoma 3

Interventions

selurampanel 1Postmortem Imaging 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adrenocortical Adenoma × Biopsy × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡